responsible for structural cell integrity and osmotic stability [1, 4, 7, 10, 12, 35, 36] . At the moment, micafungin is the firstline treatment for invasive and deep-seated Candida spp. infections and has excellent antifungal effects in vitro against the yeast strains resistant to amphotericin B and azoles, especially to C. glabrata (which is intrinsically resistant to fluconazole) [6, 16, 18, 20] . Micafungin is also recommended in treating candidiasis ranging from superficial infections, such as oral thrush and vaginitis, to systemic and potentially life-threatening diseases, e.g. esophageal candidiasis or candidemia [8, 9, 15, 19, 21] . However, there is a need to monitor the sensitivity of Candida spp. clinical isolates to echinocandins, including micafungin, in order to assess the rate of resistance to these drugs. The aim of this paper was to analyse the in vitro activity of micafungin by the E-test procedure, against 30 clinical isolates of non-albicans Candida spp. derived from different clinical specimens obtained from hospitalized patients, especially hematooncological persons. Micafungin susceptibility was assessed by the E-test procedure (AB BIODISK), using RPMI 1640 medium (SIGMA-ALDRICH) buffered to a pH 7.0 with 0.165 morpholine propanesulphonic acid (MOPS). The E-test is a quantitative technique for determining the minimum inhibitory concentration (MIC) of antimicrobial agents. MIC is defined as the lowest concentration of antimicrobial agent that will inhibit the visible growth of microorganisms. Inocula were prepared using European Committee for Antimicrobial Susceptibility Testing (EUCAST) guidelines [3] . The plates were incubated at 35°C and the MIC values were determined after 48 hours of incubation. Using standard E-test procedure, MIC was read directly from the scale in terms of mg/l at the point where the edge of the ellipse inhibition zone intersects the strip ( Figure 1 ). The MIC of micafungin for the reference yeast strain C. parapsilosis ATCC 22019 was 1.5 mg/l, i.e. within the recommended MIC range 0.25-2 mg/l. Table 2 , most of the studied clinical isolates of non-albicans Candida spp. -27 (90%) showed sensitivity to micafungin, with MIC values ranging from 0.004 to 2 mg/l, while 3 (10%) isolates, including 2 isolates of C. tropicalis and 1 isolate of C. famata were resistant to micafungin -with MIC values > 32 mg/l. As presented in Table 3 , the MIC 50 and MIC 90 values of micafungin, defined as the MIC which inhibited growth of 50% or 90% of the isolates, were 0.008 mg/l or 2 mg/l, respectively. In the case of the C. glabrata isolates, representing 50% of the isolates studied, MICs ranged from 0.004 to 0.008 mg/l, with MIC 50 at 0.004 mg/l, and MIC 90 at 0.008 mg/l. 
MATERIAL AND METHODS

RESULTS
As shown in
DISCUSSION
The increased frequency of fungal infections in recent years is associated with several factors, including inappropriate use of antifungal drugs. Our data indicate that most of the studied clinical isolates of non-albicans Candida spp. (C. glabrata, C. famata, C. tropicalis, C. inconspicua, C. lusitaniae, C. parapsilosis, C. krusei) obtained from hospitalized patients showed sensitivity to micafungin, with a MIC range of 0.004 to 2 mg/l. These data are in accord with the results presented by other authors, wherein micafungin showed good activity in vitro against a broad range of Candida spp. As reported by Nguyen et al. [23] , MIC of micafungin ranged from 0.008 to 0.125 mg/l for C. glabrata and C. krusei, and from 0.5 to 1 mg/l for C. parapsilosis. Pfaller et al. [26] found that micafungin was very active against non-albicans Candida spp. [11, 17, 22, 25, 32, 33] , who reveal that micafungin was active against clinical isolates of C. tropicalis, C. glabrata, C. parapsilosis, C. dubliniensis and C. krusei, with a MIC range from 0.002 to 1 mg/l. Of note, higher MIC values of micafungin (≥ 2 mg/l) were usually evidenced for C. tropicalis and C. parapsilosis [17, 32, 33] .
There has been a gradual increase in the incidence of C. glabrata related nosocomial infections. The treating of these infections can be difficult because this species may be resistant to fluconazole. Micafungin, a newer antifungal agent, provides an alternative and effective therapy against C. glabrata infections, especially that caused by the isolates which had developed resistance to fluconazole [6, 20] . Indeed, C. glabrata is naturally about 8-fold more insensitive to fluconazole than C. albicans. A study performed in the US showed the very high efficiency of micafungin in treating C. glabrata infections caused by the isolates resistant to fluconazole, and which were obtained from patients with candidiases of the oral cavity and throat [20] . The data presented in this paper showed that clinical isolates of C. glabrata were highly susceptible to micafungin, with MIC ranging from 0.004 to 0.016 mg/l.
Echinocandins are a relatively new group of antifungals, and, currently, resistance to them is rare [30, 31, 38] . Our data indicate that only 10% of clinical isolates of non-albicans Candida spp. (C. tropicalis, C. famata) were resistant to micafungin, with MIC ≥ 32 mg/l. It should be noted that breakpoint for micafungin-resistant strains is > 2 mg/l [3] . As found by Pfeiffer et al. [30] , MIC of micafungin for only a few clinical strains of non-albicans Candida spp., e.g. C. tropicalis and C. parapsilosis were higher than 2 mg/l, indicating insensitivity of the isolates. What is more, other authors found that some isolates of C. glabrata, C. tropicalis and C. parapsilosis obtained from different clinical materials in patients suffering from candidiases, showed MIC above 2 mg/l, this figure deciding about their resistance to this agent.
The MIC 50 and MIC 90 of micafungin for non-albicans Candida spp. isolates, obtained in the present study were 0.008 mg/l and 2 mg/l, respectively. Similar data were reported by Pfaller et al. [27] [28] [29] . These authors revealed that MIC 50 and MIC 90 of micafungin for Candida spp. As reported in this paper, the MIC 50 of micafungin for C. glabrata isolates was 0.004 mg/l and MIC 90 -0.008 mg/l. According to the data obtained by Pfaller et al. [27, 28, 29] , MIC 50 and MIC 90 of micafungin were 0.015 mg/l for C. glabrata isolates from different clinical materials obtained from several medical centers.
The presented data, showing the high in vitro activity of micafungin against non-albicans Candida spp. clinical isolates (including C. glabrata), along-side those from literature [5, 24, 34, 37] concerning the in vitro data, as well as data derived from clinical trials, point to the clinical significance of micafungin as an alternative option in the therapy of candidiases, especially invasive ones.
CONCLUSION
The data presented in this paper demonstrate that most of the studied clinical isolates of non-albicans Candida spp. showed sensitivity in vitro to micafungin. These data confirm the utility of micafungin for the therapy of the infections caused by non-albicans Candida spp., especially C. glabrata.
